NxStage Medical Inc.
News makers and game changers at the MassDevice Big 100 East 2013
Nearly 300 of the industry’s best and brightest gathered for a night of big ideas, industry insights and few cocktails last night at MassDevice.com’s Big 100 East 2013 conference in Waltham, Mass.
Medicare’s proposed dialysis cut takes a toll on device makers
Updated July 2, 2013, at 3:45 p.m. with comment from NxStage Medical.
Updated July 2, 2013, at 5 p.m. with comment from Fresenius.
Dialysis technology makers slid hard today after the Center for Medicare & Medicaid Services proposed a reimbursement decrease of more than 9% for 2014.
C-Suite shuffle at NxStage Medical
NxStage Medical (NSDQ:NXTM) appointed a new CFO, moved its former CFO over to its Kidney Care subsidiary and created a new position in the C-suite, moves that CEO & founder Jeffrey Burbank called a "positive move that expands and strengthens our management team."
Sunshine Heart seeks $25.5M in equity funding round | Wall Street Beat
Eden Prairie, Minn., and Sydney-based medical device company Sunshine Heart (ASX:SHC) is looking to raise funds in a $25.5 million equity funding round, according to document filed with the SEC earlier this month.
Medical device tax: How much are companies paying to government for healthcare reform?
In January 2013, Medical device companies began paying a 2.3% excise tax on U.S. Sales in order to pay for the Patient Protection and Affordable Care Act.
The levy is expected to generate some $30 billion over the next 10 years.
MassDevice.com is tracking the tally paid by several medical device companies, based on quarterly earnings report for the first quarter of 2013. We will update the list as more companies returns file in.
Tallies based on companies with Q1 earnings ended on March 31, 2013
NxStage Medical gains on pared Q1 losses, sales growth, affirmed guidance
NxStage Medical (NSDQ:NXTM) shares are up more than 5% today after the medical device company reported 1st-quarter sales growth and lower losses and affirmed its outlook for the rest of 2013.
FDA clears NxStage Medical’s high-flow home hemodialysis
NxStage Medical (NSDQ:NXTM) touted FDA clearance for high flow capabilities for the company’s System One home hemodialysis technology, a device the company calls the "only truly portable hemodialysis system cleared for home use."
The Lawrence, Mass.-based medical device maker plans to launch new higher flow System One devices later this year, according to a press release.
NxStage Medical taps Funari to replace Chambon as chairman | Personnel Moves
NxStage Medical (NSDQ:NXTM) named Robert Funari to replace Philippe Chambon as non-executive chairman after 15 years on the medical device company’s board of directors.
On-Q-ity folds its tents after 3 years, $26M | Wall Street Beat
On-Q-ity, which raised a $26 million Series A round back in December 2009, quietly folded its tents last year after an unsuccessful bid to develop its technology for personalized cancer detection.
Bruce Booth, a partner at Atlas Ventures, 1 of the VC shops that backed the company (and a member of On-Q-ity’s board), detailed the reasons behind the decision this week on his blog, Life Sci VC.
Novadaq, KCI spike Luna wound imaging deal | Wall Street Beat
Novadaq Technologies (TSE:NDQ) said it and wound care giant Kinetic Concepts agreed to an amicable end to the co-development deal they inked in 2011 for the Luna wound imaging device.